信立泰：SAL0140开展治疗慢性肾脏病的临床试验

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140 for the treatment of chronic kidney disease (CKD) [1] Group 1 - The company has developed SAL0140, which is an innovative small molecule drug [1] - The clinical trial approval indicates progress in the company's research and development efforts [1] - The focus on chronic kidney disease (CKD) highlights the company's commitment to addressing significant health issues [1]